Background: Postmenopausia and hypercholesterolemia are related to endothelial dysfunction, a pathogenic event in atherosclerosis. Soy protein reduces plasma cholesterol, but there is scanty information about its effect on endothelial function. Objective: To evaluate the effect of isolated soy protein compared to caseinate on plasma lipoproteins and endothelial function in postmenopausal hypercholesterolemic women. Design: Randomized, double-blind, cross-over trial. Setting: Outpatient clinic of the Catholic University of Chile. Subjects: Eighteen healthy, postmenopausal women with hypercholesterolemia were recruited, included and completed the protocol. Interventions: During the trial, all patients followed a low fat/low cholesterol diet and were randomly assigned to receive isolated soy protein or matching caseinate for 4 weeks, and then the alternative treatment until week 8. At pre-study and at the end of the first and second period, plasma lipoprotein levels and endothelial function (flow-mediated dilatation (FMD) of the brachial artery) were evaluated. Results: Plasma total and low density lipoprotein (LDL)-cholesterol concentration were significantly lower with the low fat/low cholesterol diet compared to pre-study, either with caseinate or soy protein. No significant differences in plasma lipid concentration between caseinate or soy protein interventions were observed. FMD did not change with the caseinate. In contrast, when soy protein was administered, FMD was significantly higher compared to pre-study (9.471.8% vs 5.371.2%; Po0.05) and compared to caseinate intervention (9.471.8% vs 4.971.5%; Po0.033). Conclusions: These results suggest that in postmenopausal hypercholesterolemic women, soy protein improves endothelial function, regardless of changes in plasma lipoproteins. Sponsorship: Pontificia Universidad Cató lica (DIPUC99/09E), Protein Technology International and Gynopharm Laboratory (Recalcine Group).
Introduction
The physiological decline in human ovarian function has been linked to several pathophysiological disturbances. Postmenopausal women are at increased risk of osteoporosis, gynecological malignances and cardiovascular disorders, including coronary heart disease (CHD). Moreover, postmenopausal women with hypercholesterolemia exhibit even a higher risk of CHD.
Estrogen deficiency and elevation of plasma LDL-cholesterol concentration are frequently associated with endothelial dysfunction, one of the primary pathogenic events in atherosclerosis (De Caterina, 2000; Irribarra et al, 2000) . Since estrogen replacement therapy (ERT) reduces LDL cholesterol (Whitcroft et al, 1994) , and improves endothelium-dependent vascular reactivity (Lieberman et al, 1994) , it was proposed that ERT could reduce the CHD risk. Never-theless, a large interventional study of estrogen therapy in secondary prevention of CHD not only failed to show benefits, but also demonstrated an increment in thromboembolic complications (Hulley et al, 2002) .
In China, women do not exhibit the postmenopausal decline in endothelial function and the higher risk of breast cancer of native Western women (McCrohon et al, 2000) . These findings suggest a protective role for some environmental factor(s) associated with living conditions in Eastern countries. Soy protein, an important component of Eastern diet, may constitute an attractive environmental factor for cardiovascular protection. It has been demonstrated that in different populations, soy protein supplementation reduces plasma cholesterol and triacylglycerol concentrations (Anderson et al, 1995; Griffin, 1999) and exhibits a potent antioxidant activity (Lichtenstein, 1998 ). In addition, soy feeding improves coronary endothelial function in female macaques with experimental atherosclerosis and vascular reactivity in ovariectomized rats (Honoré et al, 1997; Squadrito et al, 2000) . These effects have been at least partly attributed to soy bean compounds, named isoflavones or phytoestrogens. These components act as selective estrogen receptor modulators (SERM). SERM bind more strongly to estrogen receptor b, present in bone and vascular tissue, and with less affinity to estrogen receptor a, expressed in breast and uterus (Mäkela et al, 1999) . This receptor specificity of SERM may provide an explanation for the lack of adverse effects observed on breast cancer by SERM compared with the traditional ERT.
Since postmenopausal hypercholesterolemic women exhibit endothelial dysfunction, presumably due to dual mechanisms dependent on estrogen deficit and increased plasma cholesterol, we hypothesize that postmenopausal endothelial dysfunction may be counteracted with soy protein supplementation.
Subjects and methods

Subjects
Eighteen healthy, non-smoking, postmenopausal women with hypercholesterolemia (LDL-cholesterol concentration between 4.14 and 6.21 mmol/l and triacylglycerol less than 3.39 mmol/l) were included in the study. Pre-study characteristics are shown in Table 1 . Participants ranged in age from 47 to 70 y and their body mass indexes (in kg/m 2 ) ranged from 22.1 to 33.8. All subjects had normal liver, kidney and thyroid functions as well as normal fasting glucose concentrations. None of the patients were receiving vitamins, antioxidants, lipid-regulating agents, arginine or antihypertensive drugs and none were regularly consuming soy-protein-containing foods. Subjects gave signed informed consent to participate in the study. The protocol was approved by the Ethical Review Committee of the School of Medicine of the Pontificia Universidad Cató lica.
Study design
This was a randomized, double-blind, cross-over study. Along the trial, patients were instructed to follow a National Cholesterol Education Program (NCEP) step I diet (o 30% dietary energy as total fat, o 10% energy as saturated fat and o 300 mg/day cholesterol) and reinforced at every visit by a dietitian. The intake of soy-containing products, milk and other nutritional supplements was prohibited. At pre-study, women were randomly assigned to receive 40 g of isolated soy protein powder containing 80 mg isoflavones (60% genistein, 30% daidzein, 10% glycitein) per day or a matching caseinate for a 4-week period. Protein powders were mixed with water and consumed at morning and at bedtime (20 g at each time). Both products were provided by Protein Technologies International, St Louis, MO, USA. After this phase, patients received the alternate supplementation for an additional 4-week period (until week 8). We did not include a washout phase between periods, because previous studies had shown that it is unnecessary in randomized cross-over designs (Bonanome & Grundy, 1988) . At pre-study and after the two phases of treatment, blood samples for plasma FSH and lipid measurements were drawn and endothelial function was assessed by high-resolution vascular ultrasonography in the brachial artery. In addition, body weight, blood pressure, heart rate, adverse events and returned powder packages were registered. 
Blood analyses
After subjects had fasted for 412 h and spent 415 min in a recumbent position, blood samples were collected in tubes containing EDTA. Plasma was immediately separated by lowspeed centrifugation at 2000 Â g for 30 min at 41C. Total cholesterol and triacylglycerol were analyzed with an enzymatic method (Boehringer Mannheim, Mannheim, Germany). HDL was isolated for cholesterol measurements after precipitation of LDL and VLDL with MgCl 2 and dextran sulfate. LDL cholesterol was calculated by the Friedewald method (Friedewald et al, 1972) . FSH was determined by a specific radioimmunoassay.
Brachial artery ultrasound A non-invasive method was employed using high-resolution vascular ultrasonography as described (Celermajer, 1998) . Measurements were made between 08.00 and 10.00 , after an overnight fast and about 12 h after the last soy or caseinate beverage. Subjects were instructed not to have fat meals the night before. Room temperature was controlled at 221C. Subjects spent 15 min in a recumbent position and the nondominant arm was preferred for the test. The brachial artery was longitudinally imaged approximately 3-7 cm proximal to the antecubital crease, using a 10.5 MHz ultrasound transductor (Medison, GAIA MT, Seoul, Korea). Ultrasound was performed twice at baseline and then 1 min after release of a 5 min arterial occlusion with a blood pressure cuff (12.5 cm wide and kept at 200 mmHg) placed on the forearm. Results were expressed as percent dilatation at 1 min after flow re-establishment. Two independent investigators, unaware of dietary supplementation, performed the measurement of end-diastolic brachial artery diameter in the video and computer recordings obtained. Following flow-mediated reactivity measurement, and 5 min after rest, subjects received 300 mg nitroglycerin sublingually and the endothelium-independent dilatation response was measured 3 min after nitroglycerin administration. During every step of this procedure, blood pressure and heart rate was monitored. The inter-assay coefficient of variation was 4.8%. 
Statistical analyses
Results
Effect of isolated soy protein on body weight, blood pressure and plasma FSH and lipid concentrations Body weight was lower during soy and caseinate phases compared to pre-study, but no significant differences between the supplementations were observed. There was no significant changes in blood pressure or heart rate during the study (Table 2) . Plasma total and LDL-cholesterol concentrations significantly decreased with the NCEP step I diet, compared to pre-study conditions, either with caseinate or soy protein supplementation; however, no significant differences between the supplementations were detected (Table 2) . Plasma HDL-cholesterol concentration decreased slightly but significantly during the caseinate phase compared to pre-study, but not during soy protein supplementation. Both dietary interventions induced a reduction in plasma triacylglycerol concentrations compared to recruitment, but it reached statistical significance only during the soy protein feeding. No significant differences in plasma triacylglycerol concentrations between soy and caseinate phases were observed. FSH levels remained unchanged along the trial (Table 2) .
Effect of soy protein on arterial reactivity At pre-study, postmenopausal hypercholesterolemic women exhibited values of flow-mediated dilatation strongly suggestive of endothelial dysfunction; average: 5.3 7 1.2%; range: À2.5 to 12.6% (reference values for our adult population (older than 50 y) is about 7%). No significant changes with caseinate treatment were observed. In contrast, Values are expressed as mean 7 s.e.m.; *P o 0.05 compared to pre-study; **P o 0.03 compared to pre-study and caseinate.
soy protein supplementation induced a significant increase in flow-mediated dilatation compared to pre-study (9.4 7 1.8% vs 5.3 7 1.2%; Po0.05), and compared to caseinate (9.4 7 1.8% vs 4.9 7 1.5 %; Po0.033) ( Figure 1 , Table 2 ). These results were not related to the sequence of soy protein supply (before or after caseinate). Nitroglycerin-induced dilatation response, reflecting vascular smooth muscle function, remained constant during all phases of the study (Table 2 ). There was no significant correlation between changes in flow-mediated dilatation and those observed in plasma lipid concentrations.
Tolerance and compliance Isolated soy protein powder was well tolerated. Treatment compliance was appropriate as evidenced by 98% return of empty powder packages. Adverse events were mild and similar or lower to caseinate. Constipation was reported by 16% with soy protein intervention vs 27% with caseinate (Po0.05). Heartburn was present in 16% of individuals with soy supplementation while it was reported in 11% during caseinate (NS).
Discussion
The results of our study suggest that in postmenopausal hypercholesterolemic women, isolated soy protein improves endothelial function. This result is consistent with animal experimental studies that have shown an increment in vascular reactivity induced by soy protein phytoestrogens (Honoré et al, 1997; Squadrito et al, 2000) . The lack of differences in plasma lipid concentrations between soy and caseinate interventions suggests that the striking effect on vascular reactivity in soy-protein-fed women was not due to a reduction in cholesterol and/or triacylglycerol plasma concentration. These results are in accordance with a previous trial, carried out in menopausal and perimenopausal women, that detected a significant improvement in systemic arterial compliance, but not in plasma lipids when isoflavone pills (80 mg/day) were administered (Nestel et al, 1997) . The soy protein effect on vascular reactivity might be explained by different mechanisms, such as the antioxidant effect of soy phytoestrogens, which could decrease the inactivation of nitric oxide, one of the most potent vasodilators released by the endothelium (Mombouli & Vanhoutte, 1999) . In vitro, genistein has been shown to have antioxidant properties that can mediate this effect ( Jha HC et al). In Nestel's study, LDL oxidizability measured in vitro was not changed, despite an improvement in the arterial compliance with isoflavone supplementation; however, this result does not exclude in vivo antioxidant effects. Moreover, previous studies have shown that antioxidant supplementation with vitamins C and E (Plotnick et al, 1997) and red wine improves endothelial function. Alternatively, phytoestrogens could act directly on endothelial cell membrane, increasing nitric oxide generation by a non-genomic mechanism, as has been recently reported for estrogens (Haynes et al, 2000) . Interestingly, a recent study in postmenopausal women with severe endothelial dysfunction of unknown origin did not show any effect of phytoestrogen tablets (80 mg/day) on vascular reactivity (Simons et al, 2000) . This different result may be attributed to differences in the selected populations; our study included only women with hypercholesterolemia, but the latter study included women with endothelial dysfunction having different origins that can be unresponsive to the soy protein supplementation. Alternatively, delivery form of the isoflavone supplement may influence the effect on vascular reactivity and whole soy protein could be necessary, suggesting that other mechanisms, in addition to isoflavones' antioxidant effect may have an important role.
Regarding the effects of isolated soy protein on plasma lipid concentration, no additional reduction in cholesterol and/or triacylglycerol concentration compared to a low-fat, low-cholesterol diet was detected. It can be attributed to the lack of washout period between the two treatments resulting in carry-over effects on plasma lipids. However, the crossover design of our study may minimize this potential period effect (Bonamone & Grundy, 1988) . As mentioned before, our results on plasma lipids are similar to a previous trial carried out in perimenopausal women (Nestel et al, 1997) , but differ from other reports, including a meta-analysis that showed a 13% reduction in LDL-cholesterol concentration related to soy protein supplementation (Anderson et al, 1995; Griffin, 1999) . However, the meta-analysis included studies performed in individuals consuming a Western-type diet who may present a better response to soy protein supplementation compared to those (like the patients of our study) that consume a low-fat/low-cholesterol diet. In addition, some studies have detected a dose-dependent effect of soy isoflavones on plasma lipid concentrations Figure 1 Flow-mediated dilatation in the brachial artery of 18 postmenopausal hypercholesterolemic women at pre-study and after 4 weeks of caseinate or soy protein supplementation.
Soy protein and endothelial function AM Cuevas et al (Crouse et al, 1999; Wangen et al, 2001) , suggesting that the lack of effect in our study may be attributed to an insufficient dose of isoflavones. In support of the last hypothesis, a recent study in postmenopausal women reported that high doses of soy isoflavones (132 7 22 mg/day) induced a reduction in LDL-cholesterol plasma concentration, but it was not observed when lower doses (65 7 11 mg/day) were used (Wangen et al, 2001) . It is also possible that the lack of a 'run-in period' in our study design, allowed the inclusion of patients that had a satisfactory response to the NCEP step I diet, and then no additional effect of soy protein was observed. It is important to emphasize that our data mark the importance of diet management of hypercholesterolemic patients, confirming that in some of them, drug therapy might be unnecessary. It is also interesting to point out that a drop in HDL cholesterol is common in patients with a lowfat diet, as was observed in our study during caseinate treatment. However, it was not detected during soy protein supplementation. This effect has been reported in previous studies and might be due to the reduction in triacylglycerol plasma concentration or alternatively the estrogenic effect of soy protein may have a role. This is important to consider because of the known anti-atherogenic action of HDL cholesterol, mainly in reverse cholesterol transport (Barter & Rye, 1996) . The reduction of triacylglycerol with diet intervention should also be noted, which was accentuated by soy protein supplementation. This effect might be an additional benefit of phytoestrogens compared to natural estogens in women with hypertriglyceridemia or combined dyslipidemia.
Finally, 4% difference in brachial artery reactivity in response to isolated soy protein may appear a modest one. However, in a larger trial of patients suspected to have CHD (Schroender et al, 1999) , a 3.3% of difference in brachial artery FMD between normal and CHD populations was described (7.0 7 3.5% vs 3.7 7 4.1%, respectively). In addition, in the same study, a cut-off of 4.5% in the brachial artery FMD predicted the presence of CHD with a sensitivity and specificity of 71 and 81%, respectively.
In population at risk of CHD, there is a close relation between coronary endothelium-dependent vasomotor response to acetylcholine and FMD in the brachial artery (Anderson et al, 1995) . Recently, the prognostic value of coronary endothelial dysfunction was reported. Fourteen percent of patients presenting mild CHD and severe coronary endothelial dysfuntion, followed for an average of 28 months, presented a cardiac event compared with none of those with either normal or mild coronary endothelial dysfunction (Suwaidi et al, 2000) . In addition, in patients with non-obstructive coronary artery disease followed for a median period of 7.7 y, the presence of coronary artery endothelial dysfunction was associated with a significantly higher risk of cardiovascular events (Schachinger et al, 2000) .
In conclusion, our results demonstrate that isolated soy protein enhances endothelial function, apparently regardless of changes in plasma lipoprotein concentrations. It is possible that the antioxidant/direct action of phytoestrogen isoflavones play a role in this effect. Consequently, soy protein supplementation may be a useful alternative in cardiovascular disease prevention, with minimal risk and low cost, particularly in patients at high risk of atherosclerosis.
Additional studies, with larger number of patients, are needed to confirm our results and to clarify the underlying cellular and molecular mechanisms involved in the beneficial effect of soy protein on endothelial function.
